Effects of six months of vitamin D supplementation in patients with heart failure: A randomized double-blind controlled trial

Dalbeni, Andrea; Scaturro, Giuliana; Degan, Maurizio; Minuz, Pietro; Delva, Pietro

doi:10.1016/j.numecd.2014.02.015

Cited by 91 publications

(70 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The vitamin D3 supplement was well-tolerated and achieved sustained normal [31] noted an increase in LVEF of almost 7% after only 25 weeks in 13 patients randomised to 600,000 IU vitamin D3 at baseline and two further doses of 100,000IU at 10 and 20 weeks while the 10 patients randomised to placebo had a reduction in LVEF of more than 4%, the authors did not comment on cardiac dimensions and there was an increase in natriuretic peptide levels in both groups. In contrast to these studies, VINDICATE is a double-blind, placebo-controlled study of an oral non-calcium based daily supplement of 4000IU of vitamin D3 given for 12 months in patients with CHF due to LVSD on otherwise optimal medical therapy.…”

Section: Resultsmentioning

confidence: 99%

Calcium, phosphate and calcium phosphate product are markers of outcome in patients with chronic heart failure

et al. 2014

View full text Add to dashboard Cite

Structured abstract BackgroundPatients with chronic heart failure (CHF) secondary to left ventricular (LV) systolic dysfunction (LVSD) are frequently deficient in vitamin D. Low vitamin D levels are associated with a worse prognosis. It is unclear whether vitamin D deficiency is a marker of disease severity or plays a pathophysiological role. ObjectivesThe VitamIN D treatIng patients with Chronic heArT failurE (VINDICATE) study was designed to establish the safety and efficacy of high-dose vitamin D supplementation in patients with CHF due to LVSD. MethodsWe enrolled 229 patients (179 men) with CHF due to LVSD and vitamin D deficiency ((25(OH) vitamin D3 <50nmol/L (<20ng/mL)) into a randomised, placebo-controlled double-blind trial of vitamin D supplementation.Participants were either allocated to one year of vitamin D3 supplementation (4000IU (100 g) 25(OH)D3 daily) or matching non-calcium-based placebo.The primary endpoint was change in six-minute walk distance from baseline to 12 months. Pre-specified secondary endpoints included change in left ventricular ejection fraction at one year, and safety measures of renal function and serum calcium concentration assessed every three months. ConclusionsOne year of 100 g daily 25-OH vitamin D3 supplementation does not improve 6-minute walk distance but has beneficial effects on LV structure and function in patients on contemporary optimal medical therapy. Further studies are necessary to determine whether these translate to improvements in outcomes.

show abstract

Section: Resultsmentioning

confidence: 99%

Calcium, phosphate and calcium phosphate product are markers of outcome in patients with chronic heart failure

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Previous experimental studies have shown that cardiac contractility is enhanced by vitamin D through modulation of intracellular calcium metabolism 2, 19. Furthermore, clinical trials in humans have demonstrated that the left ventricular systolic function of heart failure patients with vitamin D deficiency improves with supplementation of vitamin D 8, 9. The lack of association between vitamin D status and left ventricular systolic dysfunction in our study may be explained by the difficulty of evaluating left ventricular systolic function in dogs with CVHD because of the effect of volume loading on the left ventricle 22…”

Section: Discussionmentioning

confidence: 99%

“…In addition, observational retrospective studies indicate that vitamin D supplementation is associated with a better prognosis in patients with heart failure and vitamin D deficiency 6, 7. Furthermore, randomized double‐blind controlled trials have shown that vitamin D supplementation improves left ventricular systolic function in patients with heart failure and vitamin D deficiency 8, 9…”

mentioning

confidence: 99%

Vitamin D Status in Different Stages of Disease Severity in Dogs with Chronic Valvular Heart Disease

Osuga

Nakamura

Morita

et al. 2015

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundIn humans with heart disease, vitamin D deficiency is associated with disease progression and a poor prognosis. A recent study showed that serum 25‐hydroxyvitamin D [25(OH)D] concentration, the hallmark of vitamin D status, was lower in dogs with heart failure than in normal dogs, and a low concentration was associated with poor outcome in dogs with heart failure.ObjectivesTo elucidate the vitamin D status of dogs with chronic valvular heart disease (CVHD) at different stages of disease severity.AnimalsForty‐three client‐owned dogs with CVHD.MethodsIn this cross‐sectional study, dogs were divided into 3 groups (14 dogs in Stage B1, 17 dogs in Stage B2, and 12 dogs in Stage C/D) according to ACVIM guidelines. Dogs underwent clinical examination including echocardiography. Serum 25(OH)D concentrations were measured in each dog.ResultsSerum 25(OH)D concentration was significantly lower in Stage B2 (median, 33.2 nmol/L; range, 4.9–171.7 nmol/L) and C/D (13.1 nmol/L; 4.9–58.1 nmol/L) than in Stage B1 (52.5 nmol/L; 33.5–178.0 nmol/L) and was not significantly different between Stage B2 and Stage C/D. Among clinical variables, there were significant negative correlations between 25(OH)D concentration and both left atrial‐to‐aortic root ratio and left ventricular end‐diastolic diameter normalized for body weight.Conclusions and Clinical ImportanceThese results indicate that vitamin D status is associated with the degree of cardiac remodeling, and the serum 25(OH)D concentration begins to decrease before the onset of heart failure in dogs with CVHD.

show abstract

“…12 -14 Over the past few years, several randomized controlled trials (RCTs) have been carried out to evaluate the effects of vitamin D supplementation in CHF patients. 15 -21 These trials investigated clinical symptoms, cardiac function, quality of life, physical performance, cardiovascular events, and inflammation, comparing vitamin D with placebo. However, some results of clinical studies are inconsistent and the conclusions are (TNF-α), C-reactive protein (CRP), interleukin-10 (IL-10), parathyroid hormone (PTH), and renin.…”

Section: Introductionmentioning

confidence: 99%

Vitamin D Supplementation in the Treatment of Chronic Heart Failure: A Meta‐analysis of Randomized Controlled Trials

Jiang

Zhang

et al. 2015

Clinical Cardiology

View full text Add to dashboard Cite

Background: In recent years, there has been growing evidence that vitamin D deficiency is associated with the development and progression of chronic heart failure (CHF). Hypothesis: Additional supplementation of vitamin D may have protective effects in patients with CHF. Methods: We searched PubMed, Embase, and Cochrane databases through June 2015 and included 7 randomized controlled trials that investigated the effects of vitamin D on cardiovascular outcomes in patients with CHF. Then, we performed a meta-analysis of clinical trials to confirm whether vitamin D supplementation is beneficial in CHF patients. The weighted mean difference (WMD) and 95% confidence interval (CI) were calculated using fixed-or random-effects models. Results: Our pooled results indicated that additional supplementation of vitamin D was not superior to conventional treatment in terms of left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, and 6-minute walk distance. Moreover, vitamin D supplementation was associated with significant decreases in the levels of tumor necrosis factor-α (WMD: −2.42 pg/mL, 95% CI: −4.26 to −0.57, P < 0.05), C-reactive protein (WMD: −0.72 mg/L, 95% CI: −1.42 to −0.02, P < 0.05), and parathyroid hormone (WMD: −13.44 pg/mL, 95% CI: −21.22 to −5.67, P < 0.05). Conclusions: Vitamin D supplementation may decrease serum levels of parathyroid hormone and inflammatory mediators in CHF patients, whereas it has no beneficial effects on improvement of left ventricular function and exercise tolerance.

show abstract

Effects of six months of vitamin D supplementation in patients with heart failure: A randomized double-blind controlled trial

Cited by 91 publications

References 29 publications

Calcium, phosphate and calcium phosphate product are markers of outcome in patients with chronic heart failure

Calcium, phosphate and calcium phosphate product are markers of outcome in patients with chronic heart failure

Vitamin D Status in Different Stages of Disease Severity in Dogs with Chronic Valvular Heart Disease

Vitamin D Supplementation in the Treatment of Chronic Heart Failure: A Meta‐analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About